Table 2. Short- and long-term outcomes of some published studies evaluating therapeutic IPC in GC patients with peritoneal metastasis.
| Author (reference) | Year | Type of study | Selection Criteria | n of patients in study group | n of patients in control group | Drug | Completeness of cytoreduction, n (%) | Morbidity, n (%) | Mortality, n (%) | Survival |
|---|---|---|---|---|---|---|---|---|---|---|
| Shimada (89) | 2002 | Retrospective | Cy (+) | 7 EIPL+ IPC+ CRS and 7 IPC+ CRS | 8 Gastrectomy | NR | NR | NR | NR | 2-y: EIPL + IPC: 57.1%; IPC: 14.3%; gastrectomy: 0% |
| Hall (90) | 2004 | Retrospective | Cy (+) | 34 HIPEC + CRS | 40 gastrectomy | MMC | HIPEC: 7 (21%); gastrectomy: 20 (58%) | HIPEC: 12 (35%); gastrectomy: 7 (17.5%) |
HIPEC: 1 (2.9%); gastrectomy: 6 (15%) | Median survival for R0: HIPEC: 36.3 months; gastrectomy: 23.3 months |
| Glehen (91) | 2004 | Prospective | PC | 49 HIPEC + CRS | – | MMC | CC 0: 5; CC 1: 20; CC 2: 24 | 13 (27%) | 2 (4%) | Median: CCR 0-1: 21.3 months; CCR 2: 6.1 months |
| Kuramoto (92) | 2009 | RCT | Cy (+) | 30 EIPL + IPC + CRS and 29 IPC + CRS | 29 Gastrectomy | NR | NR | NR | NR | 5-y: EIPL + IPC: 43.8%; IPC: 4.6%; gastrectomy: 0% |
| Glehen (88) | 2010 | Retrospective | PC | 159 HIPEC and/or EPIC | – | HIPEC: MMC/Oxaliplatin; EPIC: MMC+5-FU |
CC 0: 89 (56.0%); CC 1: 40 (25.2%); CC 2: 30 (18.8%) |
38 (27.8%) | 10 (6.5%) | Median: 9.2 months; 1-y: 43%; 3-y: 18%; 5-y: 13% |
| Yang (93) | 2010 | Retrospective | PC and/or Ascites | 32 HIPEC + CRS | – | MMC | CC 0: 11 (39.2%); CC 1: 6 (21.4%); CC 2: 8 (28.8%); CC 3: 3 (10.6%) |
4 (14.3%) | 0% | 6-month: 75%; 12-month: 50%; 18-month: 43%; 24-month: 43% |
| Yang (87) | 2011 | RCT | PC | 34 HIPEC + CRS | 34 CRS | MMC and Cisplatin | HIPEC+CRS: 20 (58.8%); CRS: 20 (58.8%) |
HIPEC + CRS: 5 (14.7%); CRS: 4 (11.7%) |
NR | Median: HIPEC + CRS: 11 months; CRS: 6.5 months |
| Rudloff (94) | 2014 | RCT | PC | 9 HIPEC + CRS + systemic CT | 7 systemic CT | Oxaliplatin | CC 0-1: 8 (88.8%) | HIPEC+ CRS+ systemic CT: 8 (88.8%) | HIPEC+ CRS+ systemic CT: 3 (33.3%) | Median: HIPEC+ CRS+ systemic CT: 11.3 months; systemic CT: 4.3 months |
| Magge (95) | 2014 | Prospective | PC | 23 HIPEC + CRS | – | MMC | CC 0: 17 (73.9%); CC 1: 5 (21.7%) |
12 (52.2%) | 1 (4.4%) | Median: 9.5 months; 1-y: 49.6%; 5-y: 17.9% |
| Topal (96) | 2014 | Prospective | PC | 32 HIPEC + CRS | – | Cisplatin | CC 0: 100% | 23 (72%) | 0% | 1-y: 90%; 2-y: 55%; 5-y: 5.6% |
| Rihuete (97) | 2018 | Prospective | PC | 35 HIPEC + CRS | – | Cisplatin+ Doxorubicin | NR | 9 (25.7%) | 2 (5.7%) | Median: 16 months; 1-y: 70.8%; 3-y: 21.3%; 5-y: 21.3% |
| Kim (98) | 2018 | Prospective | PC | 38 HIPEC + CRS | – | MMC+ Cisplatin | 21 (55.2%) | 16 (42.1%) | 2 (5.7%) | Median: 19 months |
Cy, Cytology; EIPL, extensive intraoperative peritoneal lavage; IPC, intraperitoneal chemotherapy; CRS, cytoreductive surgery; MMC, mitomycin C; 5-FU, 5-Fluorouracil; PC, peritoneal carcinomatosis; HIPEC, hyperthermic intraperitoneal chemotherapy; CC, completeness of cytoreduction; EPIC, early postoperative intraperitoneal chemotherapy; CT, chemotherapy; CR, curative resection; RCT, randomized controlled trial; NR, not reported.